Literature DB >> 9470814

Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6, (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumour necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas.

J G Asschert1, E Vellenga, H Hollema, A G van der Zee, E G de Vries.   

Abstract

Ovarian carcinoma is often associated with overexpression of cytokines that may exert autocrine and paracrine growth effects, as well as genetic alterations in (proto)oncogenes and tumour suppressor genes, such as p53. The p53 protein is not only involved in the regulation of cell cycle and apoptosis, it is also involved in the in vitro regulation of IL-6 gene expression. In this study, 30 tumours of patients with a primary diagnosis of human ovarian carcinoma were characterised for p53 expression with immunohistochemistry and analysed for the expression of M-CSF, IL-6, IL-1 beta, IL-11 and TNF-alpha with Northern blotting. Nuclear and cytoplasmic p53 staining was observed in 27% (8/30), cytoplasmic staining in 30% (9/30), and no p53 staining in 43% (13/30) of the tumours. In 70% (21/30) of the tumours, M-CSF mRNA was expressed, in 40% (12/30) TNF-alpha, and in 30% (9/30) IL-6. None of the tumours expressed IL-1 beta or IL-11. The expression of TNF-alpha occurred more frequently in M-CSF positive tumours compared to M-CSF negative tumours (52% (11/21) versus 11% (1/9), P < 0.05). TNF-alpha expression was also associated with better responses to chemotherapy (P < 0.02). M-CSF expression was associated with nuclear p53 staining (P < 0.05). The p53 positive tumours more frequently expressed one or more cytokines (88%) compared with p53 negative tumours (54%, P < 0.05). This study suggests that mutations in the p53 gene might be associated with cytokine overexpression, especially M-CSF.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9470814     DOI: 10.1016/s0959-8049(97)00240-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Association between circulating interleukin-1 beta (IL-1β) levels and IL-1β C-511T polymorphism with cervical cancer risk in Egyptian women.

Authors:  Magdy A Al-Tahhan; Rasha L Etewa; Manal M El Behery
Journal:  Mol Cell Biochem       Date:  2011-03-23       Impact factor: 3.396

Review 2.  Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.

Authors:  Linjuan Xu; Jing Cai; Qiang Yang; Hui Ding; Liying Wu; Tao Li; Zehua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

3.  Expression of interleukin-34 and colony stimulating factor-1 in the stimulated periodontal ligament cells with tumor necrosis factor-α.

Authors:  Mutsuki Kawabe; Hideki Ohyama; Nahoko Kato-Kogoe; Naoko Yamada; Koji Yamanegi; Hiroshi Nishiura; Hirotugu Hirano; Hiromitsu Kishimoto; Keiji Nakasho
Journal:  Med Mol Morphol       Date:  2014-12-30       Impact factor: 2.309

4.  Ovarian epithelial-stromal interactions: role of interleukins 1 and 6.

Authors:  Kamisha T Woolery; Patricia A Kruk
Journal:  Obstet Gynecol Int       Date:  2011-06-26

Review 5.  Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.

Authors:  Nikos G Gavalas; Alexandra Karadimou; Meletios A Dimopoulos; Aristotelis Bamias
Journal:  Clin Dev Immunol       Date:  2011-01-24

6.  IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity.

Authors:  I Kryczek; M Gryboś; L Karabon; A Klimczak; A Lange
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

7.  Stimulation of MMP-11 (stromelysin-3) expression in mouse fibroblasts by cytokines, collagen and co-culture with human breast cancer cell lines.

Authors:  Saxon Selvey; Larisa M Haupt; Erik W Thompson; Klaus I Matthaei; Michael G Irving; Lyn R Griffiths
Journal:  BMC Cancer       Date:  2004-07-25       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.